劳动
SciHub
文献互助
期刊查询
一搜即达
科研导航
即时热点
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
黑粉头头
Lv4
26
740 积分
2021-07-28 加入
最近求助
最近应助
互助留言
Eravacycline: a comprehensive review of in vitro activity, clinical efficacy, and real-world applications
2天前
已完结
Discovery and Development of Antibacterial Agents: Fortuitous and Designed
2天前
已完结
Five ways science is tackling the antibiotic resistance crisis
2天前
已完结
TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2
7天前
已关闭
Molecular Mediators and Regulators of Retinal Angiogenesis
7天前
已完结
Pharmacological modulation of Sonic Hedgehog signaling pathways in Angiogenesis: A mechanistic perspective
7天前
已完结
Biology and therapeutic targeting of vascular endothelial growth factor A
8天前
已完结
Serum GDF15 Could Predict Cardiorenal Prognosis in Patients with IgA Nephropathy
19天前
已关闭
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial
19天前
已完结
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
21天前
已完结
Scaffold-Free Endometrial Organoids Respond to Excess Androgens Associated With Polycystic Ovarian Syndrome
3年前
已驳回
Non-covalent doping of carbon nitride with biochar: Boosted peroxymonosulfate activation performance and unexpected singlet oxygen evolution mechanism
3年前
已采纳
无人应助【积分已退回】
7天前
要找的文献名是:TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2
7天前
无人应助【积分已退回】
19天前
无人应助【积分已退回】
22天前
求助的是阿柏西普8mg photon研究48周文献的附件材料,应助材料不对哈
22天前
仅求助 该文献的补充材料
23天前
想求的是: Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
24天前
系统错误【积分已退回】
28天前
求的题目是 Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
28天前
无人应助【积分已退回】
30天前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论